{"id":67354,"date":"2026-06-04T21:33:32","date_gmt":"2026-06-04T13:33:32","guid":{"rendered":"https:\/\/flcube.com\/?p=67354"},"modified":"2026-06-04T21:33:32","modified_gmt":"2026-06-04T13:33:32","slug":"hansoh-pharmaceuticals-olatorepatide-glp-1-gip-dual-agonist-accepted-for-nmpa-review-for-weight-management-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67354","title":{"rendered":"Hansoh Pharmaceutical&#8217;s Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hansoh Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review its <strong>market filing for olatorepatide (HS-20094)<\/strong>, a <strong>weekly GLP-1\/GIP dual receptor agonist<\/strong>, for the <strong>long-term weight management<\/strong> of <strong>obese or overweight individuals<\/strong>. The acceptance follows Hansoh&#8217;s landmark <strong>$1.2 billion licensing agreement<\/strong> with <strong>Regeneron Pharmaceuticals<\/strong> (Nasdaq: REGN) in June 2025.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Accepted for review (not yet approved)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Olatorepatide (HS-20094)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Long-term weight management in obese\/overweight patients<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Once-weekly subcutaneous injection<\/td><\/tr><tr><td><strong>Molecular Class<\/strong><\/td><td>GLP-1\/GIP dual receptor agonist<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This regulatory submission positions olatorepatide as one of the first domestically developed dual incretin receptor agonists to reach late-stage regulatory review in China&#8217;s rapidly expanding obesity therapeutics market.<\/p>\n\n\n\n<h2 id=\"h-strategic-partnership-amp-global-commercial-framework\" class=\"wp-block-heading\">Strategic Partnership &amp; Global Commercial Framework<\/h2>\n\n\n\n<h3 id=\"h-regeneron-licensing-agreement-june-2025\" class=\"wp-block-heading\">Regeneron Licensing Agreement (June 2025)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Value:<\/strong> Up to $1.2 billion in potential milestones and royalties<\/li>\n\n\n\n<li><strong>Territory:<\/strong> Global rights granted to Regeneron, excluding Greater China (mainland China, Hong Kong, Macau)<\/li>\n\n\n\n<li><strong>Development Responsibility:<\/strong> Regeneron leads global development outside licensed territories<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> Regeneron holds exclusive commercialization rights globally (ex-China)<\/li>\n\n\n\n<li><strong>Hansoh Retention:<\/strong> Full development and commercial rights retained for Greater China region<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-strategy-implications\" class=\"wp-block-heading\">Market Strategy Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Commercial Pathway:<\/strong> Independent commercialization in China while leveraging Regeneron&#8217;s global infrastructure elsewhere<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Substantial upfront and milestone payments de-risk Chinese development program<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> Major pharmaceutical partnership validates olatorepatide&#8217;s clinical and commercial potential<\/li>\n\n\n\n<li><strong>Resource Optimization:<\/strong> Focuses Hansoh resources on domestic market execution<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-therapeutic-innovation-amp-competitive-positioning\" class=\"wp-block-heading\">Therapeutic Innovation &amp; Competitive Positioning<\/h2>\n\n\n\n<h3 id=\"h-dual-receptor-agonist-mechanism\" class=\"wp-block-heading\">Dual Receptor Agonist Mechanism<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP-1 Component:<\/strong> Enhances glucose-dependent insulin secretion and promotes satiety<\/li>\n\n\n\n<li><strong>GIP Component:<\/strong> Augments metabolic benefits through complementary signaling pathways<\/li>\n\n\n\n<li><strong>Synergistic Effects:<\/strong> Dual activation demonstrates superior weight loss efficacy compared to single receptor agonists<\/li>\n\n\n\n<li><strong>Weekly Dosing:<\/strong> Convenient administration profile supporting long-term adherence<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-landscape-context\" class=\"wp-block-heading\">Competitive Landscape Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Leader:<\/strong> Novo Nordisk&#8217;s Wegovy (semaglutide) established as current standard-of-care<\/li>\n\n\n\n<li><strong>Next-Generation Competition:<\/strong> Multiple dual and triple agonists in development globally<\/li>\n\n\n\n<li><strong>Chinese Market Dynamics:<\/strong> Limited approved pharmacological options for obesity create significant opportunity<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Domestic manufacturing may support competitive pricing versus imported alternatives<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-outlook\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Outlook<\/h2>\n\n\n\n<h3 id=\"h-chinese-obesity-market-fundamentals\" class=\"wp-block-heading\">Chinese Obesity Market Fundamentals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Over 50% of Chinese adults classified as overweight or obese<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Minimal approved pharmacological interventions currently available<\/li>\n\n\n\n<li><strong>Healthcare Burden:<\/strong> Significant economic impact from obesity-related comorbidities<\/li>\n\n\n\n<li><strong>Government Priority:<\/strong> Growing focus on metabolic disease prevention and management<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-revenue-potential\" class=\"wp-block-heading\">Revenue Potential<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Estimated 300-400 million overweight\/obese adults in China<\/li>\n\n\n\n<li><strong>Premium Positioning:<\/strong> First-in-class dual agonist status supports premium pricing<\/li>\n\n\n\n<li><strong>Multiple Indications:<\/strong> Potential expansion to type 2 diabetes and cardiovascular risk reduction<\/li>\n\n\n\n<li><strong>Manufacturing Scale:<\/strong> Existing Hansoh infrastructure supports rapid commercial scale-up<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-chinese-pharma-innovation\" class=\"wp-block-heading\">Strategic Significance for Chinese Pharma Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Leadership:<\/strong> Demonstrates China&#8217;s capability to develop world-class peptide therapeutics<\/li>\n\n\n\n<li><strong>Global Competitiveness:<\/strong> Successful out-licensing to major US pharmaceutical company validates quality standards<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Dual agonist platform may support additional metabolic disease candidates<\/li>\n\n\n\n<li><strong>Industry Benchmark:<\/strong> Sets precedent for future Chinese biopharmaceutical global partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA filing acceptance represents a critical milestone in Hansoh&#8217;s strategy to establish olatorepatide as China&#8217;s leading domestically developed obesity therapeutic while participating in the global dual agonist revolution through its Regeneron partnership.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approval timelines, commercial performance, and partnership outcomes. Actual results may differ materially due to regulatory decisions, clinical data requirements, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060400124_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060400124_c.\"><\/object><a id=\"wp-block-file--media-d01b589c-f5f3-417a-bce4-cc5911ada46a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060400124_c.pdf\">2026060400124_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060400124_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d01b589c-f5f3-417a-bce4-cc5911ada46a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[363,1182,4361,38,86],"class_list":["post-67354","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-hot-targets","tag-market-approval-filings","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical&#039;s Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China&#039;s National Medical Products Administration (NMPA) has accepted for review its market filing for olatorepatide (HS-20094), a weekly GLP-1\/GIP dual receptor agonist, for the long-term weight management of obese or overweight individuals. The acceptance follows Hansoh&#039;s landmark $1.2 billion licensing agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) in June 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67354\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical&#039;s Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China&#039;s National Medical Products Administration (NMPA) has accepted for review its market filing for olatorepatide (HS-20094), a weekly GLP-1\/GIP dual receptor agonist, for the long-term weight management of obese or overweight individuals. The acceptance follows Hansoh&#039;s landmark $1.2 billion licensing agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) in June 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67354\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T13:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67354#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67354\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical&#8217;s Olatorepatide GLP-1\\\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication\",\"datePublished\":\"2026-06-04T13:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67354\"},\"wordCount\":577,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"Hot targets\",\"Market approval filings\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67354#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67354\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67354\",\"name\":\"Hansoh Pharmaceutical's Olatorepatide GLP-1\\\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-04T13:33:32+00:00\",\"description\":\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China's National Medical Products Administration (NMPA) has accepted for review its market filing for olatorepatide (HS-20094), a weekly GLP-1\\\/GIP dual receptor agonist, for the long-term weight management of obese or overweight individuals. The acceptance follows Hansoh's landmark $1.2 billion licensing agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) in June 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67354#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67354\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67354#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical&#8217;s Olatorepatide GLP-1\\\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical's Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China's National Medical Products Administration (NMPA) has accepted for review its market filing for olatorepatide (HS-20094), a weekly GLP-1\/GIP dual receptor agonist, for the long-term weight management of obese or overweight individuals. The acceptance follows Hansoh's landmark $1.2 billion licensing agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) in June 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67354","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical's Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication","og_description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China's National Medical Products Administration (NMPA) has accepted for review its market filing for olatorepatide (HS-20094), a weekly GLP-1\/GIP dual receptor agonist, for the long-term weight management of obese or overweight individuals. The acceptance follows Hansoh's landmark $1.2 billion licensing agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) in June 2025.","og_url":"https:\/\/flcube.com\/?p=67354","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-04T13:33:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67354#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67354"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical&#8217;s Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication","datePublished":"2026-06-04T13:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67354"},"wordCount":577,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hansoh Pharmaceutical","HKG: 3692","Hot targets","Market approval filings","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67354#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67354","url":"https:\/\/flcube.com\/?p=67354","name":"Hansoh Pharmaceutical's Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-04T13:33:32+00:00","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China's National Medical Products Administration (NMPA) has accepted for review its market filing for olatorepatide (HS-20094), a weekly GLP-1\/GIP dual receptor agonist, for the long-term weight management of obese or overweight individuals. The acceptance follows Hansoh's landmark $1.2 billion licensing agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) in June 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67354#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67354"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67354#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical&#8217;s Olatorepatide GLP-1\/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67354"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67354\/revisions"}],"predecessor-version":[{"id":67356,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67354\/revisions\/67356"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}